KDR and small cell lung carcinoma: In the phase III ETER701 study, the addition of benmelstobart (PD-L1 inhibitor) and anlotinib (VEGFR inhibitor) to EC chemotherapy markedly enhanced survival outcomes in treatment-naive ES-SCLC (25).